Abstract
Original language | English |
---|---|
Article number | 100345 |
Journal | Genetics in medicine |
Volume | 25 |
Issue number | 3 |
Early online date | 2022 |
DOIs | |
Publication status | Published - Mar 2023 |
Keywords
- Inherited retinal diseases
- Next-generation sequencing
- Optical genome mapping
- Short-read genome sequencing
- Structural variants
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Genetics in medicine, Vol. 25, No. 3, 100345, 03.2023.
Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Optical genome mapping and revisiting short-read genome sequencing data reveal previously overlooked structural variants disrupting retinal disease−associated genes
AU - de Bruijn, Suzanne E.
AU - Rodenburg, Kim
AU - Corominas, Jordi
AU - Ben-Yosef, Tamar
AU - Reurink, Janine
AU - Kremer, Hannie
AU - Whelan, Laura
AU - Plomp, Astrid S.
AU - Berger, Wolfgang
AU - Farrar, G. Jane
AU - Ferenc Kovács, Árpád
AU - Fajardy, Isabelle
AU - Hitti-Malin, Rebekkah J.
AU - Weisschuh, Nicole
AU - Weener, Marianna E.
AU - Sharon, Dror
AU - Pennings, Ronald J. E.
AU - Haer-Wigman, Lonneke
AU - Hoyng, Carel B.
AU - Nelen, Marcel R.
AU - Vissers, Lisenka E. L. M.
AU - van den Born, L. Ingeborgh
AU - Gilissen, Christian
AU - Cremers, Frans P. M.
AU - Hoischen, Alexander
AU - Neveling, Kornelia
AU - Roosing, Susanne
N1 - Funding Information: This work has been funded by the European Union’s Horizon 2020 Research and Innovation Programme under the EJP RD COFUND-EJP N° 825575 (to F.P.M.C. and S.R.). The work of K.R. and S.R. was funded by the Foundation Fighting Blindness (FFB)-career development award (CD-GE-0621-0809-RAD) (to S.R.). The work of A.H., L.E.L.M.V., and C.G. was funded by the Solve-RD project of the European Union's Horizon 2020 research and innovation programme (No. 779257). The work of K.R. and L.W. was supported by grant awards from Fighting Blindness Ireland (FB Irl; FB16FAR, FB18CRE, FB20DOC) (to F.P.M.C., S.R., and G.J.F.), The Health Research Board of Ireland (HRB;POR/2010/97) (to G.J.F.) in conjunction with Health Research Charities Ireland (HRCI; MRCG-2013-8, MRCG-2016-14) (to G.J.F.), the Irish Research Council (IRC; GOIPG/2017/1631) (to G.J.F.), and Science Foundation Ireland (SFI; 16/1A/4452) (to G.J.F.). The work of J.R. was supported by the VELUX Stiftung (to H.K., F.P.M.C. and S.R.). Á.F.K. was supported by the Hungarian Scientific Research Fund OTKA PD_21 138521 grant. This research was also supported by the Algemene Nederlandse Vereniging ter Voorkoming van Blindheid, Oogfonds , Landelijke Stichting voor Blinden en Slechtzienden , Rotterdamse Stichting Blindenbelangen , Stichting Blindenhulp , Stichting tot Verbetering van het Lot der Blinden , and Stichting Blinden-Penning (to S.R. and F.P.M.C.). Funding Information: The authors would like to thank Ellen Kater-Baats, Ronald van Beek, and Michiel Oorsprong for performing optical genome mapping and Brigitte Faas, Dominique Smeets, and Guillaume van de Zande for their help with karyotyping analysis. We thank the Department of Human Genetics and the Radboud Genome Technology Center for infrastructural and computational support. We would also like to thank Saskia van der Velde-Visser and Marlie Jacobs-Camps for DNA sample preparation and administration and Manar Salameh for technical assistance. This work has been funded by the European Union's Horizon 2020 Research and Innovation Programme under the EJP RD COFUND-EJP N° 825575 (to F.P.M.C. and S.R.). The work of K.R. and S.R. was funded by the Foundation Fighting Blindness (FFB)-career development award (CD-GE-0621-0809-RAD) (to S.R.). The work of A.H. L.E.L.M.V. and C.G. was funded by the Solve-RD project of the European Union's Horizon 2020 research and innovation programme (No. 779257). The work of K.R. and L.W. was supported by grant awards from Fighting Blindness Ireland (FB Irl; FB16FAR, FB18CRE, FB20DOC) (to F.P.M.C. S.R. and G.J.F.), The Health Research Board of Ireland (HRB;POR/2010/97) (to G.J.F.) in conjunction with Health Research Charities Ireland (HRCI; MRCG-2013-8, MRCG-2016-14) (to G.J.F.), the Irish Research Council (IRC; GOIPG/2017/1631) (to G.J.F.), and Science Foundation Ireland (SFI; 16/1A/4452) (to G.J.F.). The work of J.R. was supported by the VELUX Stiftung (to H.K. F.P.M.C. and S.R.). Á.F.K. was supported by the Hungarian Scientific Research Fund OTKA PD_21 138521 grant. This research was also supported by the Algemene Nederlandse Vereniging ter Voorkoming van Blindheid, Oogfonds, Landelijke Stichting voor Blinden en Slechtzienden, Rotterdamse Stichting Blindenbelangen, Stichting Blindenhulp, Stichting tot Verbetering van het Lot der Blinden, and Stichting Blinden-Penning (to S.R. and F.P.M.C.). Conceptualization: S.E.d.B. F.P.M.C. S.R.; Data Curation: J.C. M.R.N. L.E.L.M.V. C.G.; Formal Analysis: S.E.d.B. K.R. K.N. J.R. R.J.H.-M. L.H.-W. A.H. S.R.; Funding Acquisition: K.N. F.P.M.C. A.H. S.R.; Investigation: S.E.d.B. K.R. K.N. T.B.-Y. J.R. H.K. L.W. A.S.P. W.B. G.J.F. Á.F.K. I.F. N.W. M.E.W. D.S. R.J.E.P. L.H.-W. C.B.H.; Methodology: S.E.d.B. K.R. K.N. J.C. C.G. A.H.; Project Administration: K.N. F.P.M.C. A.H. S.R.; Supervision: H.K. G.J.F. R.J.E.P. M.R.N. L.E.L.M.V. C.G. F.P.M.C. A.H. S.R.; Validation: S.E.d.B. K.R.; Visualization: S.E.d.B. K.R.; Writing-original draft: S.E.d.B. S.R.; Writing-review and editing: S.E.d.B. K.R. K.N. J.C. T.B.-Y. J.R. H.K. L.W. A.S.P. W.B. G.J.F. Á.F.K. R.J.H.-M. I.F. N.W. M.E.W. D.S. R.J.E.P. L.H.-W. C.B.H. M.R.N. L.E.L.M.V. L.I.v.d.B. C.G. F.P.M.C. A.H. S.R. The study adhered to the tenets of the Declaration of Helsinki and was approved by the local ethics committees of the Radboud University Medical Center (Nijmegen, The Netherlands); the Rotterdam Eye Hospital (Rotterdam, The Netherlands); Amsterdam UMC (Amsterdam, The Netherlands) (NL34152.078.10), (MEC-2010-359; OZR protocol no. 2009-32); Department of Ophthalmology, The Royal Victoria Eye and Ear Hospital (Dublin, Ireland) (13-06-2011: HRA-POR201097); Ramabam Health Care Campus (Haifa, Israel); and the University Hospital of Tübingen (349/2003V and 116/2015BO2). Written informed consent was obtained from patients before DNA analysis and inclusion in this study. Publisher Copyright: © 2022 The Authors
PY - 2023/3
Y1 - 2023/3
N2 - Purpose: Structural variants (SVs) play an important role in inherited retinal diseases (IRD). Although the identification of SVs significantly improved upon the availability of genome sequencing, it is expected that involvement of SVs in IRDs is higher than anticipated. We revisited short-read genome sequencing data to enhance the identification of gene-disruptive SVs. Methods: Optical genome mapping was performed to improve SV detection in short-read genome sequencing−negative cases. In addition, reanalysis of short-read genome sequencing data was performed to improve the interpretation of SVs and to re-establish SV prioritization criteria. Results: In a monoallelic USH2A case, optical genome mapping identified a pericentric inversion (173 megabase), with 1 breakpoint disrupting USH2A. Retrospectively, the variant could be observed in genome sequencing data but was previously deemed false positive. Reanalysis of short-read genome sequencing data (427 IRD cases) was performed which yielded 30 pathogenic SVs affecting, among other genes, USH2A (n = 15), PRPF31 (n = 3), and EYS (n = 2). Eight of these (>25%) were overlooked during previous analyses. Conclusion: Critical evaluation of our findings allowed us to re-establish and improve our SV prioritization and interpretation guidelines, which will prevent missing pathogenic events in future analyses. Our data suggest that more attention should be paid to SV interpretation and the current contribution of SVs in IRDs is still underestimated.
AB - Purpose: Structural variants (SVs) play an important role in inherited retinal diseases (IRD). Although the identification of SVs significantly improved upon the availability of genome sequencing, it is expected that involvement of SVs in IRDs is higher than anticipated. We revisited short-read genome sequencing data to enhance the identification of gene-disruptive SVs. Methods: Optical genome mapping was performed to improve SV detection in short-read genome sequencing−negative cases. In addition, reanalysis of short-read genome sequencing data was performed to improve the interpretation of SVs and to re-establish SV prioritization criteria. Results: In a monoallelic USH2A case, optical genome mapping identified a pericentric inversion (173 megabase), with 1 breakpoint disrupting USH2A. Retrospectively, the variant could be observed in genome sequencing data but was previously deemed false positive. Reanalysis of short-read genome sequencing data (427 IRD cases) was performed which yielded 30 pathogenic SVs affecting, among other genes, USH2A (n = 15), PRPF31 (n = 3), and EYS (n = 2). Eight of these (>25%) were overlooked during previous analyses. Conclusion: Critical evaluation of our findings allowed us to re-establish and improve our SV prioritization and interpretation guidelines, which will prevent missing pathogenic events in future analyses. Our data suggest that more attention should be paid to SV interpretation and the current contribution of SVs in IRDs is still underestimated.
KW - Inherited retinal diseases
KW - Next-generation sequencing
KW - Optical genome mapping
KW - Short-read genome sequencing
KW - Structural variants
UR - http://www.scopus.com/inward/record.url?scp=85144381092&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.gim.2022.11.013
DO - https://doi.org/10.1016/j.gim.2022.11.013
M3 - Article
C2 - 36524988
SN - 1098-3600
VL - 25
JO - Genetics in Medicine
JF - Genetics in Medicine
IS - 3
M1 - 100345
ER -